Impact of Pre-Treatment Serum Ferritin on Response and Survival in Myelodysplastic Syndromes Treated With Azacytidine: A Multivariate Analysis.

ABSTRACT:

Background

Myelodysplastic syndromes (MDS) encompass a heterogeneous group of haematological neoplasms characterized by ineffective haematopoiesis and a variable risk of transformation to acute myeloid leukaemia (AML). Elevated serum ferritin (SF), a marker of iron overload (IO), has been linked to poorer outcomes in MDS. However, the impact of pre-treatment SF levels on azacytidine (AZA) response and survival outcomes remains unclear.

Methods

This retrospective cohort study included patients with World Health Organization-defined MDS or AML with 20%-30% bone marrow blasts treated with AZA at the Virgen de la Victoria University Hospital (Málaga, Spain) from 2007 onwards. Patients were stratified into three groups based on pre-treatment SF levels: < 500 ng/mL, 500-1000 ng/mL

SUBMITTER: Carrasco GM 

PROVIDER: S-EPMC12319231 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature